The drug has been approved and marketed in Europe as Ziextenzo since 2018. More: FDA grants Sandoz approval for Ziextenzo in oncology care Source: News
read moreThe initiative provides support in developing systems to improve health and social care evidence-based decision making. More: The return of NICE international Source: News
read moreThe new platform is called ActNow, and people “get back to the comfort of their own home quicker.” More: NHS reveals online training for speedier hospital dismissal Source: News
read moreThe Global R&D Centre will carry out R&D for potential new innovative medicines, and more than double AstraZeneca’s Shanghai R&D headcount to around 1,000. More: AZ launch new medicine research, development centres in China Source: News
read moreThe technology is the first-of-its-kind, detecting DNA and protein changes simultaneously. More: Mission Bio launches Tapestri Platform to identify accurate cancer targets Source: News
read moreMylan is focused on closing its merger with Pfizer’s Upjohn next year. But after that deal closes, the pumped-up company should have the firepower for more M&A deals, an exec said. Meanwhile, the company canned 350 products in a cleanout
read more© 1994 - 2026 B.M. Pharmaceuticals